These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

855 related articles for article (PubMed ID: 25702876)

  • 21. No apparent benefit at 5 years from a course of neoadjuvant/concurrent androgen deprivation for patients with prostate cancer treated with a high total radiation dose.
    Martinez A; Galalae R; Gonzalez J; Mitchell C; Gustafson G; Kovacs G
    J Urol; 2003 Dec; 170(6 Pt 1):2296-301. PubMed ID: 14634400
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial.
    Bolla M; Collette L; Blank L; Warde P; Dubois JB; Mirimanoff RO; Storme G; Bernier J; Kuten A; Sternberg C; Mattelaer J; Lopez Torecilla J; Pfeffer JR; Lino Cutajar C; Zurlo A; Pierart M
    Lancet; 2002 Jul; 360(9327):103-6. PubMed ID: 12126818
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of combined transient androgen deprivation and irradiation following radical prostatectomy for prostatic cancer.
    Eulau SM; Tate DJ; Stamey TA; Bagshaw MA; Hancock SL
    Int J Radiat Oncol Biol Phys; 1998 Jul; 41(4):735-40. PubMed ID: 9652832
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer.
    Zerbib M; Payan C
    Urology; 1996 Oct; 48(4):661-3. PubMed ID: 8886082
    [No Abstract]   [Full Text] [Related]  

  • 25. Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Casodex Combination Study Group.
    Schellhammer PF; Sharifi R; Block NL; Soloway MS; Venner PM; Patterson AL; Sarosdy MF; Vogelzang NJ; Schellenger JJ; Kolvenbag GJ
    Urology; 1997 Sep; 50(3):330-6. PubMed ID: 9301693
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acceptability of short term neo-adjuvant androgen deprivation in patients with locally advanced prostate cancer.
    Lamb DS; Denham JW; Mameghan H; Joseph D; Turner S; Matthews J; Franklin I; Atkinson C; North J; Poulsen M; Kovacev O; Robertson R; Francis L; Christie D; Spry NA; Tai KH; Wynne C; Duchesne G
    Radiother Oncol; 2003 Sep; 68(3):255-67. PubMed ID: 13129633
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: results of an Italian Prostate Cancer Project study.
    Boccardo F; Rubagotti A; Barichello M; Battaglia M; Carmignani G; Comeri G; Conti G; Cruciani G; Dammino S; Delliponti U; Ditonno P; Ferraris V; Lilliu S; Montefiore F; Portoghese F; Spano G
    J Clin Oncol; 1999 Jul; 17(7):2027-38. PubMed ID: 10561254
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adjuvant androgen deprivation impacts late rectal toxicity after conformal radiotherapy of prostate carcinoma.
    Sanguineti G; Agostinelli S; Foppiano F; Franzone P; Garelli S; Marcenaro M; Orsatti M; Vitale V
    Br J Cancer; 2002 Jun; 86(12):1843-7. PubMed ID: 12085173
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: a double blind, randomized, placebo-controlled crossover study.
    Diamond TH; Winters J; Smith A; De Souza P; Kersley JH; Lynch WJ; Bryant C
    Cancer; 2001 Sep; 92(6):1444-50. PubMed ID: 11745221
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Can combined androgen blockade provide long-term control or possible cure of localized prostate cancer?
    Labrie F; Candas B; Gomez JL; Cusan L
    Urology; 2002 Jul; 60(1):115-9. PubMed ID: 12100935
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial.
    Brand DH; Tree AC; Ostler P; van der Voet H; Loblaw A; Chu W; Ford D; Tolan S; Jain S; Martin A; Staffurth J; Camilleri P; Kancherla K; Frew J; Chan A; Dayes IS; Henderson D; Brown S; Cruickshank C; Burnett S; Duffton A; Griffin C; Hinder V; Morrison K; Naismith O; Hall E; van As N;
    Lancet Oncol; 2019 Nov; 20(11):1531-1543. PubMed ID: 31540791
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of androgen deprivation therapy on biochemical failure and distant metastasis in intermediate-risk prostate cancer: effects of radiation dose escalation.
    Ludwig MS; Kuban DA; Strom SS; Du XL; Lopez DS; Yamal JM
    BMC Cancer; 2015 Mar; 15():190. PubMed ID: 25885406
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate carcinoma. Analysis of time to progression. CASODEX Combination Study Group.
    Schellhammer PF; Sharifi R; Block NL; Soloway MS; Venner PM; Patterson AL; Sarosdy MF; Vogelzang NJ; Chen Y; Kolvenbag GJ
    Cancer; 1996 Nov; 78(10):2164-9. PubMed ID: 8918410
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer.
    Crawford ED
    Urology; 1995 Dec; 46(6):899-901. PubMed ID: 7502440
    [No Abstract]   [Full Text] [Related]  

  • 35. Exploratory analysis on the effect of race on clinical outcome in patients with advanced prostate cancer receiving bicalutamide or flutamide, each in combination with LHRH analogues. The Casodex Combination Study Group.
    McLeod DG; Schellhammer PF; Vogelzang NJ; Soloway MS; Sharifi R; Block NL; Venner PM; Patterson AL; Sarosdy MF; Kelley RP; Kolvenbag GJ
    Prostate; 1999 Sep; 40(4):218-24. PubMed ID: 10420149
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chemohormonal therapy as primary treatment for metastatic prostate cancer: a randomized study of estramustine phosphate plus luteinizing hormone-releasing hormone agonist versus flutamide plus luteinizing hormone-releasing hormone agonist.
    Noguchi M; Noda S; Yoshida M; Ueda S; Shiraishi T; Itoh K;
    Int J Urol; 2004 Feb; 11(2):103-9. PubMed ID: 14706014
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Determination of enzalutamide long-term safety and efficacy for castration-resistant prostate cancer patients after combined anti-androgen blockade followed by alternative anti-androgen therapy: a multicenter prospective DELC study.
    Nagahara A; Uemura M; Sato M; Nakata W; Tsujihata M; Takao T; Matsumura S; Nishimura K; Takada S; Iwanishi T; Kobayashi Y; Ishizuya Y; Takada T; Okada K; Inoue H; Kato T; Hatano K; Kawashima A; Ujike T; Fujita K; Nonomura N
    Jpn J Clin Oncol; 2024 May; 54(5):584-591. PubMed ID: 38305451
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
    D'Amico AV; Manola J; Loffredo M; Renshaw AA; DellaCroce A; Kantoff PW
    JAMA; 2004 Aug; 292(7):821-7. PubMed ID: 15315996
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Radiotherapy with or without androgen deprivation in the treatment of localized adenocarcinoma of the prostate.
    Arcangeli G; Saracino B; Micheli A; D'Angelo L; Pansadoro V; Cruciani E; Marchetti P
    Am J Clin Oncol; 1998 Feb; 21(1):1-5. PubMed ID: 9499247
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intermittent versus continuous total androgen blockade in the treatment of patients with advanced hormone-naive prostate cancer: results of a prospective randomized multicenter trial.
    de Leval J; Boca P; Yousef E; Nicolas H; Jeukenne M; Seidel L; Bouffioux C; Coppens L; Bonnet P; Andrianne R; Wlatregny D
    Clin Prostate Cancer; 2002 Dec; 1(3):163-71. PubMed ID: 15046691
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 43.